PRAME and HLA Typing: Practical Guidance for Melanoma Care

By Daniel Okafor

A single matching HLA allele is the laboratory requirement that can determine eligibility for many PRAME-directed therapies. The clinician-education segment centers on melanoma patients, with specific prognostic guidance for uveal melanoma, and offers panel guidance rather than prospective trial results.

PRAME is a tumor-associated antigen highly expressed in melanoma, with limited expression in healthy tissue. That profile has made it an increasingly attractive target for vaccines, engineered T-cell therapies and bispecific agents. The panel focuses on what treating clinicians should know about PRAME biology, its prognostic role in uveal melanoma and the HLA restriction that can govern access.

What does PRAME reveal in uveal melanoma?

PRAME has a prognostic role in uveal melanoma. In this setting, PRAME positivity combined with gene expression profiling signals a higher risk of metastatic disease.

The panel presents this as a combined risk signal, not a stand-alone treatment rule. PRAME supplies the antigen-expression finding; gene expression profiling adds the broader molecular readout considered alongside it.

For clinicians, this means PRAME positivity may carry prognostic weight in uveal melanoma, but only when read together with gene expression profiling rather than treated as a stand-alone result. The concern is disease course. A patient with both signals may face a higher risk of metastatic progression, which gives treatment planning greater urgency.

Takeaway: PRAME positivity plus gene expression profiling identifies a higher-risk uveal melanoma profile.

How does HLA restriction shape eligibility?

HLA restriction governs eligibility for many PRAME-directed therapies. Tumor cells present intracellular antigens through a specific HLA allele. The relevant allele occurs in a minority of patients and is more common in White populations.

Accordingly, HLA-negative patients may be ineligible for treatments that require that match. PRAME expression alone does not settle access to therapy; the tumor signal and the patient’s HLA context have to be considered together. In practical terms, many patients will not carry the required allele, so a promising target does not guarantee treatment eligibility.

Faculty characterize HLA typing as a straightforward germline blood test that “requires only a single matching allele.” The panel does not describe the decision as a broad HLA match across many alleles. It identifies one suitable allele as the relevant threshold for these therapies.

A defined blood test can therefore answer an access question before a clinician chooses among PRAME-directed options. The result also identifies patients who may be ineligible, making an HLA-negative finding clinically meaningful rather than simply inconclusive.

Takeaway: A patient needs the specific HLA match, not just PRAME expression, for many targeted options.

When should clinicians order HLA typing?

The panel recommends “ordering it proactively” and recording the result alongside BRAF status. HLA typing uses a straightforward germline blood test. It can enter the clinical record before treatment decisions become urgent.

Recording the HLA result beside BRAF status gives the treating team one advance view of both tumor-related treatment factors and the patient-specific restriction that can determine access. This timing avoids a last-stage search for a matching allele after PRAME-directed therapy has otherwise looked like a viable option.

For teams arranging melanoma care, the workflow has four steps:

• Consider PRAME as a target in melanoma, where the antigen is highly expressed in tumors and has limited expression in healthy tissue.
• In uveal melanoma, read PRAME positivity together with gene expression profiling as a higher metastatic-risk signal.
• Check for the specific HLA allele because it occurs in a minority of patients and HLA-negative patients may be ineligible.
• Order germline HLA typing proactively, then record the result alongside BRAF status.

Takeaway: Put HLA and BRAF results in the chart early, while treatment choices still have time.

What should clinicians carry forward?

PRAME offers a selective target in melanoma because the antigen is highly expressed in the tumor and has limited expression in healthy tissue. Its value extends beyond target selection. In uveal melanoma, PRAME positivity combined with gene expression profiling signals greater metastatic risk. HLA restriction then determines whether many vaccines, engineered T-cell therapies and bispecific agents can treat that patient at all.

The practical sequence follows directly from those facts. Establish PRAME status, interpret it in the appropriate disease context, confirm the required HLA allele and keep the HLA result beside BRAF status. That sequence turns connected laboratory findings into a treatment-access plan rather than leaving any result in isolation. It also recognizes that a promising target does not guarantee eligibility.

Takeaway: As melanoma teams evaluate PRAME-directed options, proactive HLA typing alongside BRAF status gives clinicians a practical way to prepare before treatment decisions become urgent.